Funder: Vertex Pharmaceuticals
Due Dates: Rolling (most programs) | February 27, 2026 (Beta thalassemia & Sickle cell disease ISS RFP)
Funding Amounts: No fixed cap; awards must represent fair market value and generally not exceed 30% of an organization's annual operating budget. Multi-year and milestone-based funding possible.
Summary: Grants support independent medical education, patient advocacy, and research initiatives in cystic fibrosis, sickle cell disease, type 1 diabetes, and related areas.
Key Information: Applications must be submitted at least 60 days before the event (grants) or by the stated RFP deadline (disease-specific ISS).